A naming problem
'Prurigo' has a specific dermatological meaning: chronic itch in which scratching produces papules or nodules. Aquagenic pruritus is largely lesion-free, so it does not really belong to the family whose name this site borrowed.
This page exists because the confusion is real and consequential. If you arrived here searching for prurigo and you have visible lumps, nodules or persistent skin changes, the rest of this site is probably not about your condition — and the treatments differ substantially.
Contemporary definitions of chronic prurigo require three things together: itch lasting six weeks or more, repeated scratching or rubbing, and resulting pruriginous lesions — papules, nodules or plaques — which then feed the itch–scratch cycle. Aquagenic pruritus has the itch but characteristically not the primary lesions.
The nodular archetype: relentless high-intensity itch with firm nodules, hyperkeratosis and vertical dermal fibrosis, plus increased mast cells and dense sensory nerve fibres. Uncommon — around 3.27 per 100,000 in English data — and very high burden. Driven substantially by IL-31, IL-4, IL-13, IL-17 and IL-22 with nerve growth factor.
Crops of intensely itchy red papules on trunk and limbs, frequently excoriated, leaving pigment change. Less fibrotic and non-nodular compared with prurigo nodularis, and easily mistaken for insect bites, urticaria or eczema.
A hypersensitivity reaction to insect or arachnid bites — fleas and mites on cats and dogs are the commonest culprits. Clusters of itchy papules on uncovered skin, often with a central punctum, flaring in summer and autumn. Usually self-limiting over months to years as tolerance develops.
A chronic photodermatosis: itchy papules and nodules on sun-exposed sites, appearing hours to days after UV exposure, sometimes with cheilitis or conjunctivitis. Strongly associated with HLA-DRB1*0407 and reported particularly in people of Latin American and indigenous North American descent.
Prurigo nodularis now has dedicated biologics, and this is where confusing the conditions does real harm. Nemolizumab, which blocks the IL-31 receptor, achieved a four-point or greater improvement on the peak-pruritus scale in 41–56% of patients across randomised trials, as early as week four. Dupilumab, which blocks IL-4 receptor α, also shows significant itch and nodule improvement.
Neither is indicated for aquagenic pruritus. They target a Th2/Th17/Th22 cytokine axis that drives lesion formation and fibrosis — machinery that is not the problem in water-triggered, lesion-free itch, where the implicated pathway is neurosensory. Asking for the wrong biologic on the basis of a shared word wastes an appointment at best.
| Chronic prurigo | Aquagenic pruritus | |
|---|---|---|
| Primary lesions | Papules, nodules, plaques from scratching | None |
| Trigger | Often none identifiable; UV or insects in specific subtypes | Contact with water, including sweat |
| Main drivers | IL-31, IL-4/IL-13, Th17/Th22, NGF, fibrosis | C-fibres, MrgprD, acetylcholine, fibrinolytic activity |
| Work-up | UV testing, environment and insect assessment, inflammatory screen | Water challenge, full blood count for myeloproliferative disease |
| Targeted treatment | Nemolizumab, dupilumab, and older systemics | No licensed agent; β-alanine has patient-level evidence only |